Shot Block, FDA Rejects Regeneron Pharmaceuticals (NASDAQ: REGN) Twice Regeneron Pharmaceuticals faced a second rejection from the FDA for its lymphoma therapy, odronextamab, due to issues identified at a Catalent manufacturing...
The US government's plan to allow Medicare and Medicaid to cover Eli Lilly's weight loss drugs The US government’s plan to allow Medicare and Medicaid to cover Eli Lilly’s weight loss drugs starting in 2026 and 2027. This move includes Eli Lilly’s...
Fed up; Trump express his anger with Fed Chair Powell Early Friday morning President Donald Trump on Truth Social on Friday: Jerome “Too Late” Powell, a stubborn MORON, must substantially lower interest rates, NOW. IF HE CONTINUES TO REFUSE, THE BOARD SHOULD ASSUME...
Cash is King; MPLX (NYSE: MPLX) to acquire Northwind Midstream for $2.375 billion in cash MPLX LP (NYSE: MPLX) announced it has entered into a definitive agreement to acquire Northwind Delaware Holdings LLC for $2.375 billion in cash, subject to customary purchase...
Show me the money; Verisk (NASDAQ: VRSK) to acquire AccuLynx for $2.35 billion in cash deal Verisk Analytics Inc. (NASDAQ: VRSK) announced it has entered into a definitive agreement to acquire AccuLynx for $2.35 billion in cash. The transaction will be funded through...
Apellis (NASDAQ:APLS) stock soars after FDA approves first C3G treatment Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy...
